- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02023749
Effects of Nut Consumption on Metabolic Syndrome
December 23, 2013 updated by: Nan Hee Kim, Ministry of Food and Drug Safety, Korea
Effects of Nut Consumption on Metabolic Syndrome in Korean Adults - A Randomized Controlled Dietary Intervention Trial
This study aimed to investigate the effects of nut consumption on metabolic parameters and biomarkers related to inflammation, oxidative stress, and endothelial function in Korean adults with metabolic syndrome.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A randomized, controlled, parallel, dietary intervention study was designed.
Subjects with metabolic syndrome and body mass index ≥23 kg/m2 were randomized to the Nut group, which were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks; or allocated to the Control group.
Metabolic markers were evaluated at baseline and at the end of the study.
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gyeonggi-do
-
Ansan-si, Gyeonggi-do, Korea, Republic of, 425-707
- Department of Endocrinology and Metabolism, Korea University Ansan Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
35 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects were enrolled if their body mass index (BMI) was ≥23 kg/m2 and they met the criteria for metabolic syndrome.
Exclusion Criteria:
- Subjects were excluded if they had a nut allergy, peptic disorder, a history of cancer or cardiovascular disease including coronary artery disease, heart valve disease, or stroke, or established chronic diseases such as chronic renal insufficiency or cirrhosis. Subjects were also excluded if they:1) were receiving treatment with hypoglycemic agents for diabetes or had HbA1c >7%; 2) were receiving corticosteroid treatment; 3) had started antihypertensive or lipid-lowering agents, or changed their doses within the previous month; 4) had a weight change ≥5 % of body weight during the three months prior to the study; 5) were pregnant; or 6) were regular nut consumers (>15g/day of nuts at least three times a week).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Nut group
Subjects were supplemented with 30 g of mixed nuts including walnuts, peanuts, and pine nuts for 6 weeks
|
|
|
No Intervention: Control group
Control group maintained their usual diet without nut supplement
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
metabolic parameters
Time Frame: 6 weeks
|
lipid profiles, body mass index, waist circumference, blood pressure, fasting glucose, insulin, hemoglobin A1c and homeostasis model assessment of insulin resistance
|
6 weeks
|
|
inflammation markers
Time Frame: 6 weeks
|
white blood cell count, high-sensitive C-reactive protein, Interleukin-6, adiponectin, serum and urine malondialdehyde, oxidized low-density lipoprotein, vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM)
|
6 weeks
|
|
Endo-peripheral artery tonometry (EndoPAT) index
Time Frame: 6 weeks
|
EndoPAT index was assessed to evaluate endothelial function by using a finger plethysmograph based on non-invasive peripheral artery tonometry.
|
6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Nan Hee Kim, Prof, Department of Endocrinology and Metabolism, Korea University Ansan Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2012
Primary Completion (Actual)
August 1, 2012
Study Completion (Actual)
October 1, 2012
Study Registration Dates
First Submitted
December 17, 2013
First Submitted That Met QC Criteria
December 23, 2013
First Posted (Estimate)
December 30, 2013
Study Record Updates
Last Update Posted (Estimate)
December 30, 2013
Last Update Submitted That Met QC Criteria
December 23, 2013
Last Verified
December 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12161MFDS118 (Other Grant/Funding Number: Ministry of Food and Drug Safety)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Syndrome
-
Sun Yat-sen UniversityNot yet recruitingMetabolic Syndrome Risk Factors | Metabolic Syndrome (MetS)China
-
Meihua JiThe Luhe Teaching Hospital of the Capital Medical UniversityRecruiting
-
Meihua JiThe Luhe Teaching Hospital of the Capital Medical UniversityEnrolling by invitationMetabolic Syndrome (MetS)China
-
National University Health System, SingaporeRecruitingMetabolic Syndrome | Metabolic Syndrome (MetS)Singapore
-
Hacettepe UniversityCompletedMetabolic Syndrome | Metabolic Syndrome Obesity | Metabolic Syndrome ParametersTurkey
-
Universidad de los Andes, ChileCompleted
-
University of KhartoumMinistry of Higher Education and Scientific Research, Republic of SudanCompletedMetabolic Syndrome in Postmenopausal FemalesSudan
-
SanofiBristol-Myers SquibbCompletedMetabolic Syndrome xUnited States
-
University of Missouri-ColumbiaRecruitingGlucose Metabolism Disorders | Metabolic Syndrome | Metabolic Syndrome, Protection AgainstUnited States
-
Mayo ClinicCompleted
Clinical Trials on Nut group
-
Novindiet ClinicTehran University of Medical Sciences; University of NottinghamCompletedObesity | OverweightIran, Islamic Republic of
-
Novindiet ClinicTehran University of Medical Sciences; University of NottinghamCompleted
-
Oslo University HospitalCompletedObesity | Diabetes | Metabolic SyndromeNorway
-
University of GuamNational Cancer Institute (NCI); University of Hawaii Cancer Research CenterCompletedTobacco Cessation | Betel Nut ChewerGuam
-
University of California, DavisRecruiting
-
Rio de Janeiro State UniversityCompleted
-
Northumbria UniversityInternational Nut and Dried Fruit CouncilCompletedCognitive Function | Intestinal Microbiota | Urinary MetabolitesUnited Kingdom
-
Universidade Federal FluminenseActive, not recruitingInflammation | Chronic Kidney Diseases | Inflammatory Response | Oxidative Stress | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 3B | Intestinal Microbiota | Chronic Kidney Disease Stage 3ABrazil
-
Loma Linda UniversityCompletedHeart Diseases | Inflammation | Cardiovascular Risk FactorUnited States
-
University of Roma La SapienzaCompleted